Oral Thin Films Market Report 2025

This Oral Thin Films report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The oral thin films market size has grown rapidly in recent years. It will grow from $4.48 billion in 2024 to $5.03 billion in 2025 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to patient compliance, pediatric and geriatric patients, rapid drug delivery, chronic diseases, over-the-counter (otc) medications.

The oral thin films market size is expected to see rapid growth in the next few years. It will grow to $8.72 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to specialty pharmaceuticals, precision medicine, mental health medications, oral vaccines, telemedicine services. Major trends in the forecast period include drug delivery technologies, remote care, bioavailability enhancement, travel and on-the-go usage, allergen-free formulations.

The growing demand for thin film drug delivery systems is fueling the expansion of the oral thin film market. Thin films have emerged as a promising alternative to traditional dosage forms due to their convenience, self-administration, and fast-dissolving nature, making them a versatile drug delivery platform. These films are taken orally and do not require water for ingestion, allowing for efficient drug absorption. Oral thin films (OTFs) are particularly patient-friendly due to their rapid dissolution rate. As a result, the demand for thin film drug delivery systems is rising, driving increased interest in oral thin films. In the United States, cardiovascular disease affects over half the population. For example, in January 2023, a report from The American Cancer Society, a US-based nonprofit organization, noted that at least 42% of newly diagnosed cancers in the US, excluding non-melanoma skin cancer, accounted for approximately 820,000 cases in 2023, with a projected 840,000 cases in 2024. This underscores the growing need for advanced drug delivery systems to ensure effective treatment. Consequently, the increasing demand for thin film drug delivery systems is boosting the growth of the oral thin film market.

Leading companies in the oral thin films market are focusing on innovative products like Rizaport to boost their revenue. Rizaport is a branded oral thin film that contains rizatriptan benzoate, a 5-HT1 receptor agonist and the active ingredient in Merck & Co.'s Maxalt. For example, in February 2024, CD Formulation, a US-based drug formulation company, introduced its oral thin film technology. This product is designed for easy administration, particularly for patients who have difficulty swallowing, and ensures rapid absorption by dissolving in the oral cavity, bypassing the digestive system for quicker onset of action. This cutting-edge drug delivery system enhances bioavailability, provides accurate dosing for individualized treatment, and improves both convenience and medication adherence, especially in urgent situations.

Product approvals are playing a crucial role in market dynamics, as demonstrated by IntelGenx Technologies Corp.'s FDA approval for Rizafilm in April 2023. Rizafilm, an orally soluble film administering Rizaport outside the US, provides migraine patients with a quick-dissolving and effective alternative without the need for swallowing a tablet. This approval further solidifies the position of oral thin films in addressing various patient needs.

In September 2022, LTS LOHMANN Therapie-Systeme AG, a Germany-based company specializing in drug delivery systems, acquired Tapemark Inc. Tapemark Inc., a US-based Contract Development and Manufacturing Organization (CDMO), is renowned for its expertise in transdermal drug delivery systems and oral thin films, enhancing LTS's capabilities in these areas.

Major companies operating in the oral thin films market include ZIM Laboratories Limited, NAL Pharma, Cure Pharmaceutical Holding Corp., IntelGenx Corp., Kyu Kyu Pharmaceutical Co. Ltd., Sunovion Pharmaceuticals Inc., Seoul Pharma Co. Ltd., Aquestive Therapeutics Inc., Shilpa Therapeutics Pvt. Ltd., Mylan Inc., LIVKON Pharmaceuticals Pvt. Ltd., Panacea Biotec Ltd., Adare Pharmaceuticals Inc., APR Applied Pharma Research SA, BioDelivery Sciences International Inc., Sumitomo Dainippon Pharma Co. Ltd., Indivior PLC, LTS Lohmann Therapie-Systeme AG, Tesa Labtec GmbH, Pfizer Inc., Sanofi S.A., Merck & Co. Inc., Novartis International AG, Roche Holding AG, Johnson & Johnson, GlaxoSmithKline plc, Bayer AG, Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb Company, Novo Nordisk A/S, AstraZeneca plc.

North America was the largest region in the oral thin film market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral thin film market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the oral thin film market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The oral thin films market consists of sales of orally disintegrating and orally dissolving films. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

An oral thin film (OTF) is an extremely thin polymeric film designed for application in the mouth. The primary purpose of oral thin films is to deliver therapeutic substances into the oral cavity or the gastrointestinal tract, facilitating absorption and direct transportation into the circulatory system.

The main types of oral thin films include sublingual films and fast-dissolving dental/buccal films. Sublingual films rapidly dissolve under the tongue, facilitating quick absorption through the tissue and direct entry into the bloodstream. These films are often used in the treatment of conditions such as opioid misuse disorder recovery. Additionally, oral thin films are employed in the treatment of various conditions like schizophrenia, migraine, opioid dependence, nausea, and vomiting. These films are typically distributed through hospital pharmacies, retail pharmacies, and other relevant distribution channels.

The oral thin films market research report is one of a series of new reports that provides oral thin films market statistics, including oral thin films industry global market size, regional shares, competitors with an oral thin films market share, detailed oral thin films market segments, market trends and opportunities, and any further data you may need to thrive in the oral thin films industry. This oral thin films market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.